Next-generation sequencing of TP53 mutations negates the need for FISH assessment in the investigation of TP53 aberrations
Mark Catherwood(University of Ulster), Anna Schuh(University of Oxford), Adele Timbs, Amir Hayat(Abdul Wali Khan University Mardan), Ezzat Elhassadi, JohnP Quinn, Niamh Appleby(National Health Service), Dara Bruce, Ken Mills(Johns Hopkins University), Dana Wrensch Donaldson, Patrick Thornton(Beaumont Hospital), Doriane Cavalieri(University of Clermont Auvergne), Patricia D. Murphy(Newark Beth Israel Medical Center), Sarah Lawless(Belfast Health and Social Care Trust), Hélène Dreau(University of Oxford), M. Cahill(The Nature Conservancy), Anjelica Hodgson
Leukemia & lymphoma/Leukemia and lymphoma
March 16, 2020
Cited by 0
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.
|PubMed|1989|963
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890